0000000000361934

AUTHOR

Aitana Braza-boïls

showing 8 related works from this author

Clinical characteristics and determinants of the phenotype in TMEM43 arrhythmogenic right ventricular cardiomyopathy type 5.

2020

Arrhythmogenic right ventricular cardiomyopathy type V (ARVC-5) is the most aggressive heterozygous form of ARVC. It is predominantly caused by a fully penetrant mutation (p.S358L) in the nondesmosomal gene TMEM43-endemic to Newfoundland, Canada. To date, all familial cases reported worldwide share a common ancestral haplotype. It is unknown whether the p.S358L mutation by itself causes ARVC-5 or whether the disease is influenced by genetic or environmental factors. The purpose of this study was to examine the phenotype, clinical course, and the impact of exercise on patients with p.S358L ARVC-5 without the Newfoundland genetic background. We studied 62 affected individuals and 73 noncarrie…

AdultMalemedicine.medical_specialtyDNA Mutational AnalysisMutation MissenseDisease030204 cardiovascular system & hematologyVentricular Function LeftRight ventricular cardiomyopathySudden cardiac deathElectrocardiography03 medical and health sciences0302 clinical medicinePhysiology (medical)Internal medicinemedicineGeneticsHumans030212 general & internal medicineExerciseArrhythmogenic Right Ventricular DysplasiaEjection fractionTMEM43business.industryIncidence (epidemiology)HaplotypeMembrane ProteinsStroke VolumeDNAmedicine.diseasePhenotypePedigree3. Good healthPhenotypeMutation (genetic algorithm)CardiologyFemaleCardiology and Cardiovascular MedicinebusinessArrhythmogenic right ventricular cardiomyopathyArrhythmia
researchProduct

MicroRNA expression profile in endometriosis: its relation to angiogenesis and fibrinolytic factors

2014

Study question Could an aberrant microRNA (miRNA) expression profile be responsible for the changes in the angiogenic and fibrinolytic states observed in endometriotic lesions? Summary answer This study revealed characteristic miRNA expression profiles associated with endometriosis in endometrial tissue and endometriotic lesions from the same patient and their correlation with the most important angiogenic and fibrinolytic factors. WHAT IS ALREADY KNOWN?: An important role for dysregulated miRNA expression in the pathogenesis of endometriosis is well documented. However, to the best of our knowledge, there are no reports of the relationship between angiogenic and fibrinolytic factors and mi…

AdultVascular Endothelial Growth Factor Amedicine.medical_specialtyAngiogenesisEndometriosisEndometriosisEndometriumThrombospondin 1EndometriumYoung Adultchemistry.chemical_compoundInternal medicinePlasminogen Activator Inhibitor 1microRNAmedicineHumansNeovascularization Pathologicbusiness.industryRehabilitationObstetrics and GynecologyMicroRNA Expression ProfileMiddle Agedmedicine.diseaseUrokinase-Type Plasminogen ActivatorVascular endothelial growth factorMicroRNAsVascular endothelial growth factor AEndocrinologymedicine.anatomical_structureReproductive MedicinechemistryCase-Control StudiesCancer researchFemalebusinessFibrinolytic agentHuman Reproduction
researchProduct

miRNAs Regulation and Its Role as Biomarkers in Endometriosis.

2016

MicroRNAs (miRNAs) are small non-coding RNAs (18-22 nt) that function as modulators of gene expression. Since their discovery in 1993 in C. elegans, our knowledge about their biogenesis, function, and mechanism of action has increased enormously, especially in recent years, with the development of deep-sequencing technologies. New biogenesis pathways and sources of miRNAs are changing our concept about these molecules. The study of the miRNA contribution to pathological states is a field of great interest in research. Different groups have reported the implication of miRNAs in pathologies such as cancer, diabetes, cardiovascular, and gynecological diseases. It is also well-known that miRNAs…

0301 basic medicineendometriosisnon-coding RNAEndometriosisReviewBioinformaticsCatalysisInorganic Chemistrylcsh:Chemistry03 medical and health sciencesEndometriumRNA TransfermicroRNARNA Small CytoplasmicMedicineHumansRNA MessengerPhysical and Theoretical ChemistryRNA Small InterferingMolecular Biologylcsh:QH301-705.5SpectroscopyRegulation of gene expressionmicroRNAbusiness.industryOrganic ChemistryCancerGeneral Medicinemedicine.diseaseNon-coding RNAComputer Science ApplicationsMicroRNAs030104 developmental biologylcsh:Biology (General)lcsh:QD1-999Gene Expression RegulationGinecologiaBiomarker (medicine)biomarkerFemalebusinessBiogenesisFunction (biology)Biomarkers
researchProduct

The EP300/TP53 pathway, a suppressor of the Hippo and canonical WNT pathways, is activated in human hearts with arrhythmogenic cardiomyopathy in the …

2021

Aim Arrhythmogenic cardiomyopathy (ACM) is a primary myocardial disease that typically manifests with cardiac arrhythmias, progressive heart failure and sudden cardiac death (SCD). ACM is mainly caused by mutations in genes encoding desmosome proteins. Desmosomes are cell-cell adhesion structures and hubs for mechanosensing and mechanotransduction. The objective was to identify the dysregulated molecular and biological pathways in human ACM in the absence of overt heart failure. Methods and results Transcriptomes in the right ventricular endomyocardial biopsy samples from three independent individuals carrying truncating mutations in the DSP gene and 5 control samples were analyzed by RNA-S…

0301 basic medicinePhysiologyCardiomyopathy030204 cardiovascular system & hematologyBiologyMechanotransduction CellularBiological pathway03 medical and health sciences0302 clinical medicinePhysiology (medical)medicineHumansMechanotransductionEP300Wnt Signaling PathwayArrhythmogenic Right Ventricular DysplasiaHeart FailureHippo signaling pathwayWnt signaling pathwayArrhythmias CardiacOriginal Articlesmedicine.diseaseCell biologyDeath Sudden Cardiac030104 developmental biologyCardiomyopathy Gene expression Hippo pathway RNA-Sequencing TP53 WNT pathwayHeart failureTumor Suppressor Protein p53Signal transductionCardiomyopathiesCardiology and Cardiovascular MedicineE1A-Associated p300 ProteinCardiovascular Research
researchProduct

Micro-RNA profile and proteins in peritoneal fluid from women with endometriosis: their relationship with sterility.

2018

Objective: To define the microRNA (miRNA) profile and its relationship with cytokines content in peritoneal fluid (PF) from endometriosis patients. Design: Case-control study. Setting: University hospital, research institute. Patient(s): One hundred twenty-six women with endometriosis (EPF) and 45 control women (CPF). Main Outcomes Measure(s): MiRNA arrays were prepared from six EPF and six CPF. Quantitative reverse transcription-polymerase chain reaction validation of nine selected miRNAs (miR-29c-3p, -106b-3p, -130a-3p, -150-5p, -185-5p, -195-5p, -451a, -486-5p, and -1343-5p) was performed. Vascular endothelial growth factor-A (VEGF-A), thrombospondin-1 (TSP-1), urokinase plasminogen acti…

0301 basic medicineendometriosisAdultProteomicsMMP3AngiogenesisEndometriosisEndometriosisEnzyme-Linked Immunosorbent AssayAndrology03 medical and health sciences0302 clinical medicinePregnancymedicineAscitic FluidHumansAngiogenic ProteinsMacrophage inflammatory proteinOligonucleotide Array Sequence Analysis030219 obstetrics & reproductive medicinemicroRNAbusiness.industryPeritoneal fluidGene Expression ProfilingObstetrics and GynecologyInterleukinProteinsMiddle Agedmedicine.diseaseFold changeMicroRNAs030104 developmental biologyperitoneal fluidFertilityReproductive MedicineinflammationCase-Control StudiesCytokinesFemaleAngiogenesisInflammation MediatorsbusinessTranscriptomePlasminogen activatorInfertility FemaleFertility and sterility
researchProduct

Analysis of early biochemical markers and regulation by tin protoporphyrin IX in a model of spontaneous osteoarthritis

2011

Abstract Age-related changes in joint tissues lead to osteoarthritis (OA). Detection of early changes in OA patients may help to initiate treatments before the establishment of irreversible joint destruction. STR/ort mice develop with age a severe degenerative joint disease that resembles human OA thus allowing the investigation of biochemical markers as well as new treatments in an accelerated time frame. We have analyzed the changes in serum levels of different mediators during the early phases of idiopathic OA in STR/ort mice. Serum levels of matrix metalloproteinase-3 (MMP-3) but not those of tumor necrosis factor-α, interleukin(IL)-1β, IL-17 or prostaglandin E 2 correlated with histopa…

MaleAgingmedicine.medical_specialtyPathologyMetalloporphyrinsmedicine.medical_treatmentDrug Evaluation PreclinicalProtoporphyrinsMice Inbred StrainsOsteoarthritisMatrix metalloproteinaseBiochemistryMiceEndocrinologyInternal medicineOsteoarthritisGeneticsmedicineAnimalsEnzyme InhibitorsMolecular BiologyBiochemical markersbusiness.industryInterleukinCell BiologyClinical Enzyme TestsTin protoporphyrin IXmedicine.diseaseArthritis ExperimentalEarly DiagnosisEndocrinologyHeme Oxygenase (Decyclizing)Disease ProgressionBiomarker (medicine)Matrix Metalloproteinase 3Tumor necrosis factor alphaInflammation MediatorsbusinessBiomarkersProstaglandin EExperimental Gerontology
researchProduct

Regulation of the inflammatory response by tin protoporphyrin IX in the rat anterior cruciate ligament transection model of osteoarthritis

2010

The purpose of this study was to investigate several inflammatory mediators and cartilage degradation molecules as possible biomarkers of joint lesion in the anterior cruciate ligament transection (ACLT) model of osteoarthritis in rats. We also assessed whether the treatment with the anti-inflammatory agent tin protoporphyrin IX (SnPP) reduces the progression of disease. Our results indicate that serum levels of interleukin (IL)-6 and PGE2 are significantly increased in ACLT rats 10 weeks after surgery, whereas the increases in IL-1β and tumor necrosis-α were not significant. In addition, our data suggest that IL-17 is the main pro-inflammatory cytokine in the ACLT joint. We have shown that…

Cartilage ArticularMalemedicine.medical_specialtyMetalloporphyrinsAnterior cruciate ligamentType II collagenProtoporphyrinsInflammationOsteoarthritisDinoprostoneLesionchemistry.chemical_compoundInternal medicineOsteoarthritisHyaluronic acidmedicineAnimalsOrthopedics and Sports MedicineAnterior Cruciate LigamentEnzyme InhibitorsRats WistarCartilage oligomeric matrix proteinbiologybusiness.industryAnterior Cruciate Ligament InjuriesCartilageAnti-Inflammatory Agents Non-Steroidalmedicine.diseaseStifleRatsSurgeryDisease Models AnimalEndocrinologymedicine.anatomical_structurechemistrybiology.proteinCytokinesmedicine.symptombusinessBiomarkersJournal of Orthopaedic Research
researchProduct

Avarol inhibits TNF-a generation and NF-kB activation in human cells and in animal models

2007

Avarol is a marine sesquiterpenoid hydroquinone with interesting pharmacological properties including anti-inflammatory and antipsoriatic effects. In the present study we evaluated the pharmacological effect of avarol on some inflammatory parameters related to the pathogenesis of psoriasis. Avarol inhibited tumor necrosis factor-alpha (TNF-alpha) generation in stimulated human monocytes (IC(50) 1 microM) and TNF-alpha-induced activation of nuclear factor-kappaB (NF-kappaB)-DNA binding in keratinocytes. In the mouse air pouch model, administration of avarol produced a dose-dependent reduction of TNF-alpha generation (ED(50) 9.2 nmol/pouch) as well as of interleukin (IL)-1beta, prostaglandin …

Keratinocytesmedicine.medical_specialtymedicine.medical_treatmentAnti-Inflammatory AgentsAntineoplastic AgentsBiologyPharmacologyMonocytesGeneral Biochemistry Genetics and Molecular BiologyCell LineMicechemistry.chemical_compoundDownregulation and upregulationIn vivoInternal medicinemedicineAnimalsHumansPsoriasisGeneral Pharmacology Toxicology and PharmaceuticsPeroxidaseInflammationHyperplasiaDose-Response Relationship DrugTumor Necrosis Factor-alphaNF-kappa B p50 SubunitInterleukinNF-κBGeneral MedicineDisease Models AnimalEndocrinologymedicine.anatomical_structureEicosanoidchemistryTetradecanoylphorbol AcetateFemaleTumor necrosis factor alphaEpidermisInflammation MediatorsKeratinocyteSesquiterpenesProstaglandin E
researchProduct